Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism

Pharmacogenomics Journal

Volumn 5, Issue 1, 2005, Pages 60-69

  Tiwari, A K ^a   Deshpande, S N ^b,c   Rao, A R ^d   Bhatia, T ^c   Mukit, S R ^c   Shriharsh, V ^c   Lerer, B ^e   Nimagaonkar, V L ^c,f   Thelma, B K ^a,c  

^a UNIVERSITY OF DELHI   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

^c Indo US Proj Schizophrenia Genet   (India)

^d ICAR INDIAN AGRICULTURAL STATISTICS RESEARCH INSTITUTE   (India)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Association; CYP1A2; North India; Pharmacogenetics; Single nucleotide polymorphisms; Tardive Dyskinesia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CYTOCHROME P450 1A2; NEUROLEPTIC AGENT;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; INDIA; LONG TERM CARE; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING HABIT; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CYTOCHROME P-450 CYP1A2; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 13544259943     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500282     Document Type: Article

References (46)

1. Yassa R, Ananth J. Familial Tardive dyskinesia. Am J Psychiatry 1981; 138: 1618-1619.
2. Muller DJ, Schulze TG, Knapp M, Held T, Krauss H, Weber T et al. Familial occurrence of Tardive dyskinesia. Acta Psychiatr Scand 2001; 104: 375-379.
3. Kane JM, Smith JM. Tardive Dyskinesia: prevalence and risk factors 1959 to 1979. Arch Gen Pscychiaty 1982; 39: 473-481.
4. Bergen J, Kitchin R, Berry G. Predictors of the course of Tardive Dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992; 32: 580-594.
5. Jeste DW, Wyatt RJ. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor sensitivity? J Clin Psychiatry 1981; 42: 455-457.
6. Casey DE, Geralch J, Bjondal N. Levodopa and receptor sensitivity modification in tardive dyskinesia. Psychopharmacology 1982; 78: 89-92.
7. Geralch J, Casey DE. Sulpiride in tardive dyskinesia. Acta Psychiatr Scand 1984; 311: 93-102.
8. Mehsul CK, Casey DE. Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment. Brain Res 1989; 489: 338-346.
9. Gordon JH, Fields JZ. A permanent dopamine receptor upregulation in the ovariectomized rat. Pharmacol Biochem Behav 1989; 33: 123-125.
10. Basile VS, Masellis M, Potkin SG, Kennedy JL. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 2002; 11: 2517-2530.
11. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R et al. Pharmacogenetics of Tardive Dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-118.
12. Shimada T, Yamazaki H, Mimura M, Inui Y, Gungerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Ther 1994; 270: 414-423.
13. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenia patients with tardive dyskinesia. J Clin Psychpharmacol 1995; 15: 211-216.
14. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-26.
15. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA et al. A functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410-417.
16. Smith SS, Fiore MC. The epidemiology of tobacco use, dependence and cessation in the United States. Primary Care 1999; 26: 433-461.
17. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamakati T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-808.
18. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C>A polymorphism in intron I of the cytochrome P 50 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
19. Guy W (ed). Early Clinical Drug Evaluation Unit b Assessment Manual. US Department of health and human services, National Institute of Mental Health (NIMH): Rockville, Maryland 1976.
20. Schultze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001; 105: 498-501.
21. Chong S, Tan E, Tan CH, Mythily. Smoking and Tardive Dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003; 28: 185-189.
22. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27.
23. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992; 160: 41-45.
24. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992; 18: 701-715.
25. Chevalier D, Cauffiez C, Allorge D, Lo-Guidice JM, Lhermitte M, Lafitte JJ et al. Five novel natural allelic variants - 951 A>C, 1042 G>A (D348N), 1156A>T (I386F), 1217 G>A (C406Y) and 1291 C>T (C4341Y) - of the mutation in a French Caucasian population. Hum Mutat 2001; 17: 355-360.
26. Nebert DW. Polymorphism in drug metabolizing enzymes: what is their clinical relevance and why do they exists? Am J Hum Genet 1997; 60: 265-271.
27. Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with mouse and rat orthologous gene, and differences in liver mRNA expression. Mol Endocrinol 1989; 3: 1399-1408.
28. Pickwell GV, Shih H, Quattrochi LC. Interaction of upstream stimulatory factor proteins with an E-box located within the human CYP1A2 5′-flanking gene contributes to basal transcriptional gene activation. Biochem Pharmacol 2003; 65: 1087-1096.
29. Hamdy SI, Hiratsuka M, Narahara K, Endo N, El-Enany M, Moursi N et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmocol 2003; 55 321-324.
30. Coon H, Jensen S, Holik J, Hoff M, Myles-Worsley M, Reimherr F et al. Genomic scan for genes predisposing to schizophrenia. Am Med Genet 1994; 54: 59-71.
31. Kaufman CA, Suarez B, Malaspina D, Pepel J, Svarakic D, Meyer J et al. NIMH genetics initiative millenium schizophrenia consortium: linkage analysis of African American pedigrees. Am J Med Genet 1998; 88: 29-33.
32. Stober G, Saar K, Ruschendorf F, Meyer J, Nurnberg G, Jatzke S et al. Splitting schizophrenia: periodic catatonia - susceptibility locus on chromosome 15q15. Am J Hum Genet 2000; 67: 1201-1207.
33. Freedman A, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. PNAS 1997; 94: 587-592.
34. Riley B P, Makoff A, Mogudi-Carter M, Jenkins T, Williamson RD, Murray R. Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern Africal Bantu families. Am J Med Genet 2000; 96: 196-201.
35. Liu C, Hwo H, Lin M, Ou-yang W, Lee S, Fann C et al. Suggestive evidence for linkage of schizophrenia markers at chromosome 15q13-14 in Taiwanese families. Am J Med Genet 2000; 105: 658-661.
36. Morse DC, Steim AP, Thomas PE, Lowndess HE. Distribution and induction of cytochrome P450 1A1 and 1A2 in rat brain. Toxicol Appl Pharmacol 1998; 152: 232-239.
37. Nurnberger Jr JI, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J et al. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 1994; 5: 849-859.
38. Deshpande SN, Mathur MNL, Das SK, Bhatia T, Sharma SD, Nimgaonkar VL. A hindi version of the diagnostic interview for genetic studies. Schizophr Bull 1998; 24: 489-493.
39. Schooler NR, Kane JM. Research diagnoses for tardive Dyskinesia. Arch Gen Prychiatry 1982; 39: 486-487.
40. Simpson GM, Angus JWS. Drug-induced extrapyramidal disorder - a rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 20-27.
41. Sambrook J, Fritsch EE, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd edn, Cold Spring Harbor Laboratory press: Cold Spring Harbor, NY, 1989.
42. Gordon D, Finch SJ, Nothnagel M, Ott J. Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms. Hum Heredity 2002; 54: 22-33.
43. Gordon D, Levenstien MA, Finch SJ, Ott J. Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies. Pacific Symposium on Biocomputing. 2003, pp 490-501.
44. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978-989.
45. Stephens M, Donnelly P. Comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003; 73: 1162-1169.
46. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995; 59: 97-105.